KROS Keros Therapeutics, Inc.

NASDAQ
$12.00

Keros Therapeutics, Inc. (KROS) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $1.41 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +23.2% since its last earnings release on November 5, 2026.

Keros Therapeutics Beat Consensus Estimates
Thursday, November 5, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($1.41)
Rev est $350K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.44

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.